Matthew S Lara1, William S Holland1, Danielle Chinn1, Rebekah A Burich1, Primo N Lara1, David R Gandara1, Karen Kelly1, Philip C Mack2. 1. Division of Hematology-Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Davis, CA. 2. Division of Hematology-Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Davis, CA. Electronic address: pcmack@ucdavis.edu.
Abstract
BACKGROUND: Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is initially effective in non-small-cell lung cancer (NSCLC) patients with tumors harboring activating mutations of EGFR, most subsequently develop acquired resistance. One recognized resistance mechanism occurs through activation of bypass signaling via the hepatocyte growth factor (HGF)-MET pathway. INC-280 is a small molecule kinase inhibitor of MET. We sought to demonstrate the activity of INC-280 on select NSCLC cell lines both as a single agent and in combination with erlotinib using exogenous HGF to simulate MET up-regulation. METHODS: Four NSCLC cell lines (HCC827, PC9, H1666, and H358) were treated with either single-agent INC-280 or in combination with erlotinib with or without HGF. The activity of the drug treatments was measured by cell viability assays. Immunoblotting was used to monitor expression of EGFR/pEGFR, MET/pMET, GAB1/pGAB1, AKT/pAKT, and ERK/pERK as well as markers of apoptosis (PARP and capase-3 cleavage) in H1666, HCC827, and PC9. RESULTS: As a single agent, INC-280 showed minimal cytotoxicity despite potent inhibition of MET kinase activity at concentrations as low as 10 nM. Addition of HGF prevented erlotinib-induced cell death. The addition of INC280 to HGF-mediated erlotinib-resistant models restored erlotinib sensitivity for all cell lines tested, associated with cleavage of both PARP and caspase-3. In these models, INC-280 treatment was sufficient to restore erlotinib-induced inhibition of MET, GAB1, AKT, and ERK in the presence of HGF. CONCLUSION: Although the MET inhibitor INC-280 alone had no discernible effect on cell growth, it was able to restore sensitivity to erlotinib and promote apoptosis in NSCLC models rendered erlotinib resistant by HGF. These data provide a preclinical rationale for an ongoing phase 1 clinical trial of erlotinib plus INC-280 in EGFR-mutated NSCLC.
BACKGROUND: Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is initially effective in non-small-cell lung cancer (NSCLC) patients with tumors harboring activating mutations of EGFR, most subsequently develop acquired resistance. One recognized resistance mechanism occurs through activation of bypass signaling via the hepatocyte growth factor (HGF)-MET pathway. INC-280 is a small molecule kinase inhibitor of MET. We sought to demonstrate the activity of INC-280 on select NSCLC cell lines both as a single agent and in combination with erlotinib using exogenous HGF to simulate MET up-regulation. METHODS: Four NSCLC cell lines (HCC827, PC9, H1666, and H358) were treated with either single-agent INC-280 or in combination with erlotinib with or without HGF. The activity of the drug treatments was measured by cell viability assays. Immunoblotting was used to monitor expression of EGFR/pEGFR, MET/pMET, GAB1/pGAB1, AKT/pAKT, and ERK/pERK as well as markers of apoptosis (PARP and capase-3 cleavage) in H1666, HCC827, and PC9. RESULTS: As a single agent, INC-280 showed minimal cytotoxicity despite potent inhibition of MET kinase activity at concentrations as low as 10 nM. Addition of HGF prevented erlotinib-induced cell death. The addition of INC280 to HGF-mediated erlotinib-resistant models restored erlotinib sensitivity for all cell lines tested, associated with cleavage of both PARP and caspase-3. In these models, INC-280 treatment was sufficient to restore erlotinib-induced inhibition of MET, GAB1, AKT, and ERK in the presence of HGF. CONCLUSION: Although the MET inhibitor INC-280 alone had no discernible effect on cell growth, it was able to restore sensitivity to erlotinib and promote apoptosis in NSCLC models rendered erlotinib resistant by HGF. These data provide a preclinical rationale for an ongoing phase 1 clinical trial of erlotinib plus INC-280 in EGFR-mutated NSCLC.
Authors: S Yoshikawa; M Kukimoto-Niino; L Parker; N Handa; T Terada; T Fujimoto; Y Terazawa; M Wakiyama; M Sato; S Sano; T Kobayashi; T Tanaka; L Chen; Z-J Liu; B-C Wang; M Shirouzu; S Kawa; K Semba; T Yamamoto; S Yokoyama Journal: Oncogene Date: 2012-02-20 Impact factor: 9.867
Authors: Xiangdong Liu; Qian Wang; Gengjie Yang; Cindy Marando; Holly K Koblish; Leslie M Hall; Jordan S Fridman; Elham Behshad; Richard Wynn; Yu Li; Jason Boer; Sharon Diamond; Chunhong He; Meizhong Xu; Jincong Zhuo; Wenqing Yao; Robert C Newton; Peggy A Scherle Journal: Clin Cancer Res Date: 2011-09-14 Impact factor: 12.531
Authors: Anne S Tsao; Xi Ming Tang; Bradley Sabloff; Lianchun Xiao; Hisayuki Shigematsu; Jack Roth; Margaret Spitz; Waun Ki Hong; Adi Gazdar; Ignacio Wistuba Journal: J Thorac Oncol Date: 2006-03 Impact factor: 15.609
Authors: William S Holland; Danielle C Chinn; Primo N Lara; David R Gandara; Philip C Mack Journal: J Cancer Res Clin Oncol Date: 2014-10-17 Impact factor: 4.553
Authors: Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne Journal: Cancer Cell Date: 2010-01-19 Impact factor: 31.743
Authors: Caroline E McCoach; Aiming Yu; David R Gandara; Jonathan W Riess; Daniel P Vang; Tiahong Li; Primo N Lara; Matthew Gubens; Frances Lara; Philip C Mack; Laurel A Beckett; Karen Kelly Journal: JCO Precis Oncol Date: 2021-01-14
Authors: Elena M Tosca; Glenn Gauderat; Sylvain Fouliard; Mike Burbridge; Marylore Chenel; Paolo Magni Journal: CPT Pharmacometrics Syst Pharmacol Date: 2021-10-28